Veracyte (VCYT) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook
March 10, 2016 4:05 PM ESTSOUTH SAN FRANCISCO, Calif., March 10, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and business progress for the quarter and full year ended December 31, 2015, and provided financial guidance for 2016.
"We had an excellent year in 2015, driving the growth of our Afirma Gene Expression Classifier (GEC), gaining payer coverage and reimbursement, and advancing our pulmonology program," said Bonnie Anderson, president and chief executive officer of Veracyte. "We are firmly establishing Afirma as a new standard... More
